Whole genome characterization of hepatitis B virus quasispecies with massively parallel pyrosequencing

Clinical Microbiology and Infection

Volumn 21, Issue 3, 2015, Pages 280-287

  Li, F ^a   Zhang, D ^a   Li, Y ^b   Jiang, D ^c   Luo, S ^a,d   Du, N ^a   Chen, W ^a   Deng, L ^e   Zeng, C ^a  

^a Chinese Academy of Sciences and China National Center for Bioinformation   (China)

^b THIRD MILITARY MEDICAL UNIVERSITY   (China)

^c Department of Clinical Laboratory Jining Hospital for Infectious Diseases   (China)

^d UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

^e NANCHANG UNIVERSITY   (China)

Author keywords

Hepatitis B virus; Liver disease; Mutations; Quasispecies; Sequencing

Indexed keywords

AMPLICON; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; HEPATITIS B VIRUS; HEPATITIS B VIRUS GENOTYPE B; HEPATITIS B VIRUS GENOTYPE C; HUMAN; LIVER DISEASE; MUTATION RATE; NONHUMAN; POINT MUTATION; POLYMERASE CHAIN REACTION; POPULATION; PRIORITY JOURNAL; PYROSEQUENCING; VIRAL QUASISPECIES PYROSEQUENCING; VIRUS DETECTION; VIRUS GENOME; VIRUS MUTATION; AMINO ACID SUBSTITUTION; CHRONIC HEPATITIS B; CLUSTER ANALYSIS; DISEASE COURSE; GENE DELETION; GENETIC VARIATION; GENETICS; GENOMICS; HETEROZYGOTE; HIGH THROUGHPUT SEQUENCING; MUTATION; PATHOLOGY; VIROLOGY; VIRUS GENE;

HEPATITIS B VIRUS;

AMINO ACID SUBSTITUTION; CARRIER STATE; CLUSTER ANALYSIS; DISEASE PROGRESSION; GENES, VIRAL; GENETIC VARIATION; GENOME, VIRAL; GENOMICS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MUTATION; SEQUENCE DELETION;

EID: 84933516529     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1016/j.cmi.2014.10.007     Document Type: Article

References (27)

1. Seeger C., Mason W.S. Hepatitis B virus biology. Microbiol Mol Biol Rev 2000, 64:51-68.
2. Gunther S., Fischer L., Pult I., Sterneck M., Will H. Naturally occurring variants of hepatitis B virus. Adv Virus Res 1999, 52:25-137.
3. Chotiyaputta W., Lok A.S. Hepatitis B virus variants. Nat Rev Gastroenterol Hepatol 2009, 6:453-462.
4. Parekh S., Zoulim F., Ahn S.H., Tsai A., Li J., Kawai S., et al. Genome replication, virion secretion, and e antigen expression of naturally occurring hepatitis B virus core promoter mutants. J Virol 2003, 77:6601-6612.
5. Tu H., Bonura C., Giannini C., Mouly H., Soussan P., Kew M., et al. Biological impact of natural cooh-terminal deletions of hepatitis b virus x protein in hepatocellular carcinoma tissues. Cancer Res 2001, 61:7803-7810.
6. Wang H.C., Chang W.T., Chang W.W., Wu H.C., Huang W., Lei H.Y., et al. Hepatitis B virus pre-s2 mutant upregulates cyclin a expression and induces nodular proliferation of hepatocytes. Hepatology 2005, 41:761-770.
7. Astrovskaya I., Tork B., Mangul S., Westbrooks K., Măndoiu I., Balfe P., et al. Inferring viral quasispecies spectra from 454 pyrosequencing reads. BMC Bioinformatics 2011, 12(Suppl. 6):S1.
8. Menzo S., Vincenti D., Solmone M., Prosperi M., Bruselles A., Abbate I., et al. Low-abundance drug resistance mutations: extending the HIV paradigm to hepatitis B virus. J Infect Dis 2009, 200:1798-1799. author reply 1799-800.
9. Solmone M., Vincenti D., Prosperi M.C., Bruselles A., Ippolito G., Capobianchi M.R. Use of massively parallel ultradeep pyrosequencing to characterize the genetic diversity of hepatitis B virus in drug-resistant and drug-naive patients and to detect minor variants in reverse transcriptase and hepatitis B S antigen. J Virol 2009, 83:1718-1726.
10. Margeridon-Thermet S., Shulman N.S., Ahmed A., Shahriar R., Liu T., Wang C., et al. Ultra-deep pyrosequencing of hepatitis b virus quasispecies from nucleoside and nucleotide reverse-transcriptase inhibitor (nrti)-treated patients and nrti-naive patients. J Infect Dis 2009, 199:1275-1285.
11. Reuman E.C., Margeridon-Thermet S., Caudill H.B., Liu T., Borroto-Esoda K., Svarovskaia E.S., et al. A classification model for g-to-a hypermutation in hepatitis B virus ultra-deep pyrosequencing reads. Bioinformatics 2010, 26:2929-2932.
12. Homs M., Buti M., Quer J., Jardí R., Schaper M., Tabernero D., et al. Ultra-deep pyrosequencing analysis of the hepatitis b virus precore region and main catalytic motif of the viral polymerase in the same viral genome. Nucleic Acids Res 2011, 39:8457-8471.
13. Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association The guideline of prevention and treatment for chronic hepatitis B (2010 version). Zhonghua Liu Xing Bing Xue Za Zhi 2011, 32:405-415. [Chinese].
14. Hamady M., Walker J.J., Harris J.K., Gold N.J., Knight R. Error-correcting barcoded primers for pyrosequencing hundreds of samples in multiplex. Nat Methods 2008, 5:235-237.
15. Zhang D., Dong P., Zhang K., Deng L., Bach C., Chen W., et al. Whole genome HBV deletion profiles and the accumulation of pres deletion mutant during antiviral treatment. BMC Microbiol 2012, 12:307.
16. Zhu Y., Jin Y., Guo X., Bai X., Chen T., Wang J., et al. Comparison study on the complete sequence of hepatitis b virus identifies new mutations in core gene associated with hepatocellular carcinoma. Cancer Epidemiol Biomarkers Prev 2010, 19:2623-2630.
17. Yin J., Xie J., Liu S., Zhang H., Han L., Lu W., et al. Association between the various mutations in viral core promoter region to different stages of hepatitis b, ranging of asymptomatic carrier state to hepatocellular carcinoma. Am J Gastroenterol 2011, 106:81-92.
18. Li M.S., Lau T.C., Chan S.K., Wong C.H., Ng P.K., Sung J.J., et al. The g1613a mutation in the hbv genome affects hbeag expression and viral replication through altered core promoter activity. PLoS One 2011, 6:e21856.
19. Zhang K.Y., Imazeki F., Fukai K., Arai M., Kanda T., Mikata R., et al. Analysis of the complete hepatitis b virus genome in patients with genotype c chronic hepatitis and hepatocellular carcinoma. Cancer Sci 2007, 98:1921-1929.
20. Le T., Chiarella J., Simen B.B., Hanczaruk B., Egholm M., Landry M.L., et al. Low-abundance hiv drug-resistant viral variants in treatment-experienced persons correlate with historical antiretroviral use. PLoS One 2009, 4:e6079.
21. Hosono S., Tai P.C., Wang W., Ambrose M., Hwang D.G., Yuan T.T., et al. Core antigen mutations of human hepatitis b virus in hepatomas accumulate in mhc class ii-restricted t cell epitopes. Virology 1995, 212:151-162.
22. Desmond C.P., Bartholomeusz A., Gaudieri S., Revill P.A., Lewin S.R. A systematic review of t-cell epitopes in hepatitis B virus: identification, genotypic variation and relevance to antiviral therapeutics. Antivir Ther 2008, 13:161-175.
23. Salfeld J., Pfaff E., Noah M., Schaller H. Antigenic determinants and functional domains in core antigen and e antigen from hepatitis B virus. J Virol 1989, 63:798-808.
24. Wynne S.A., Crowther R.A., Leslie A.G. The crystal structure of the human hepatitis B virus capsid. Mol Cell 1999, 3:771-780.
25. Chisari F.V., Filippi P., McLachlan A., Milich D.R., Riggs M., Lee S., et al. Expression of hepatitis b virus large envelope polypeptide inhibits hepatitis B surface antigen secretion in transgenic mice. J Virol 1986, 60:880-887.
26. Mun H.S., Lee S.A., Kim H., Hwang E.S., Kook Y.H., Kim B.J. Novel f141l pre-s2 mutation in hepatitis B virus increases the risk of hepatocellular carcinoma in patients with chronic genotype c infections. J Virol 2011, 85:123-132.
27. Yuan T.T., Lin M.H., Chen D.S., Shih C. A defective interference-like phenomenon of human hepatitis B virus in chronic carriers. J Virol 1998, 72:578-584.